Illumina's Next Big Move: Distributed Diagnostics
In recent years, investors have loudly cheered big announcements from DNA sequencing leader Illumina (NASDAQ: ILMN). From the introduction of refrigerator-sized sequencing machines capable of processing thousands of human genomes per year to reaching the symbolic benchmark represented by the $1,000 human genome, there's been no shortage of headline-grabbing updates.
But the latest trajectory-altering move doesn't seem to be getting nearly the same attention. Illumina has been inking partnerships across and beyond the genomics industry to provide customers and competitors access to its global base of installed machines. Whether Illumina co-develops novel in vitro diagnostic (IVD) test kits or simply allows established tests to use its instruments, the goal is the same: to improve patient outcomes with distributed diagnostics.
Here's why the move deserves more attention from investors.
Source Fool.com
